Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Feb;40(2):408–412. doi: 10.1128/aac.40.2.408

Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.

G Del Río 1, F Dalet 1, L Aguilar 1, J Caffaratti 1, R Dal-Ré 1
PMCID: PMC163124  PMID: 8834888

Abstract

The efficacy and safety of rufloxacin (400 mg, single dose) were compared to those of norfloxacin (400 mg twice a day for 3 days) for the treatment of women with uncomplicated cystitis. In addition, urine levels, drug level/MIC ratio, and urine antibacterial activity 72 to 84 h after treatment initiation were determined in a subgroup of patients for pharmacodynamic assessment. A total of 203 women were included and treated in this open, randomized clinical trial; 100 patients received norfloxacin, whereas 103 received rufloxacin. Of these, 156 (74 and 82 patients in the norfloxacin and rufloxacin groups, respectively) were considered bacteriologically evaluable. At the first follow-up visits (3 to 12 days after starting the treatment), bacteriological cure rates were 99 and 94% for norfloxacin and rufloxacin, respectively. Seventy-nine percent (119 of 150) of bacteriologically cured patients attended a long-term follow-up visit (4 to 6 weeks after starting the treatment), where a relapse rate of 4% (2 of 54) and 5% (3 of 64) were found in the norfloxacin and rufloxacin groups, respectively. The pharmacodynamic evaluation performed in 35 patients showed similar median urine levels (approximately equal to 25 micrograms/ml) and urine antibacterial activity for both treatment groups against initial isolates, despite a higher norfloxacin level/MIC ratio due to the lower MIC of norfloxacin. Twenty-one patients (20%) in the rufloxacin group and 12 patients (12%) in the norfloxacin group reported 39 and 16 adverse events, respectively, almost all of them being mild and lasting < 24 h. Overall, gastrointestinal reactions were the most frequent adverse events reported. However, 12 patients treated with rufloxacin reported 15 central nervous system adverse events. This study shows that single doses of rufloxacin are as effective as a norfloxacin 3-day standard treatment in uncomplicated cystitis. The results obtained with rufloxacin are consistent with its pharmacodynamic properties.

Full Text

The Full Text of this article is available as a PDF (188.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguiar J. M., Chacon J., Canton R., Baquero F. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections. J Antimicrob Chemother. 1992 Mar;29(3):349–350. doi: 10.1093/jac/29.3.349. [DOI] [PubMed] [Google Scholar]
  2. Backhouse C. I., Matthews J. A. Single-dose enoxacin compared with 3-day treatment for urinary tract infection. Antimicrob Agents Chemother. 1989 Jun;33(6):877–880. doi: 10.1128/aac.33.6.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brumfitt W., Hamilton-Miller J. M. Consensus viewpoint on management of urinary infections. J Antimicrob Chemother. 1994 May;33 (Suppl A):147–153. doi: 10.1093/jac/33.suppl_a.147. [DOI] [PubMed] [Google Scholar]
  4. Cruciani M., Monzillo V., Navarra A., Tinelli C., Concia E. Antibacterial activity after a single-dose of norfloxacin, ofloxacin and pipemidic acid detected in urine of volunteers. Drugs Exp Clin Res. 1988;14(8):533–537. [PubMed] [Google Scholar]
  5. Hooton T. M., Johnson C., Winter C., Kuwamura L., Rogers M. E., Roberts P. L., Stamm W. E. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob Agents Chemother. 1991 Jul;35(7):1479–1483. doi: 10.1128/aac.35.7.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Imbimbo B. P., Broccali G., Cesana M., Crema F., Attardo-Parrinello G. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob Agents Chemother. 1991 Feb;35(2):390–393. doi: 10.1128/aac.35.2.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Israel D., Gillum J. G., Turik M., Harvey K., Ford J., Dalton H., Towle M., Echols R., Heller A. H., Polk R. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1993 Oct;37(10):2193–2199. doi: 10.1128/aac.37.10.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jardin A., Cesana M. Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group. Antimicrob Agents Chemother. 1995 Jan;39(1):215–220. doi: 10.1128/aac.39.1.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kisicki J. C., Griess R. S., Ott C. L., Cohen G. M., McCormack R. J., Troetel W. M., Imbimbo B. P. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers. Antimicrob Agents Chemother. 1992 Jun;36(6):1296–1301. doi: 10.1128/aac.36.6.1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Klastersky J., Daneau D., Swings G., Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis. 1974 Feb;129(2):187–193. doi: 10.1093/infdis/129.2.187. [DOI] [PubMed] [Google Scholar]
  11. Klietmann W., Cesana M., Rondel R. K., Focht J. Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 1993 Nov;37(11):2298–2306. doi: 10.1128/aac.37.11.2298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kunin C. M. Urinary tract infections in females. Clin Infect Dis. 1994 Jan;18(1):1–12. doi: 10.1093/clinids/18.1.1. [DOI] [PubMed] [Google Scholar]
  13. Malinverni R., Glauser M. P. Comparative studies of fluoroquinolones in the treatment of urinary tract infections. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S153–S163. doi: 10.1093/clinids/10.supplement_1.s153. [DOI] [PubMed] [Google Scholar]
  14. Mattina R., Cocuzza C. E., Cesana M. Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group. Infection. 1993 Mar-Apr;21(2):106–111. doi: 10.1007/BF01710743. [DOI] [PubMed] [Google Scholar]
  15. Norrby S. R. Short-term treatment of uncomplicated lower urinary tract infections in women. Rev Infect Dis. 1990 May-Jun;12(3):458–467. doi: 10.1093/clinids/12.3.458. [DOI] [PubMed] [Google Scholar]
  16. Norrby S. R. The design of clinical trials with antibiotics. Eur J Clin Microbiol Infect Dis. 1990 Jul;9(7):523–529. doi: 10.1007/BF01964296. [DOI] [PubMed] [Google Scholar]
  17. Ravizzola G., Pinsi G., Pirali F., Colombrita D., Foresti I., Peroni L., Turano A. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity. Drugs Exp Clin Res. 1989;15(1):11–15. [PubMed] [Google Scholar]
  18. Reeves D. S., Lacey R. W., Mummery R. V., Mahendra M., Bint A. J., Newsom S. W. Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study. J Antimicrob Chemother. 1984 May;13 (Suppl B):99–105. doi: 10.1093/jac/13.suppl_b.99. [DOI] [PubMed] [Google Scholar]
  19. Rubin R. H., Shapiro E. D., Andriole V. T., Davis R. J., Stamm W. E. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S216–S227. doi: 10.1093/clind/15.supplement_1.s216. [DOI] [PubMed] [Google Scholar]
  20. Stamm W. E., Hooton T. M. Management of urinary tract infections in adults. N Engl J Med. 1993 Oct 28;329(18):1328–1334. doi: 10.1056/NEJM199310283291808. [DOI] [PubMed] [Google Scholar]
  21. Wise R., Andrews J. M., Matthews R., Wolstenholme M. The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother. 1992 Jun;29(6):649–660. doi: 10.1093/jac/29.6.649. [DOI] [PubMed] [Google Scholar]
  22. Wise R., Johnson J., O'Sullivan N., Andrews J. M., Imbimbo B. P. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J Antimicrob Chemother. 1991 Dec;28(6):905–909. doi: 10.1093/jac/28.6.905. [DOI] [PubMed] [Google Scholar]
  23. Zeiler H. J., Beermann D., Wingender W., Förster D., Schacht P. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection. 1988;16 (Suppl 1):S19–S23. doi: 10.1007/BF01650502. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES